What changed for Gastroparesis
A plain English summary of what recently moved in the public data Voxsanity tracks for Gastroparesis. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials on record 268 to 273 (+5)
Newly subsidised on the PBS
No PBS-reviewed medicines are tracked for Gastroparesis yet, so new PBS listings cannot be reported for it. This is a gap in what Voxsanity has mapped, not a statement that no medicines are subsidised — check the PBS directly.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 36 trials tracked for Gastroparesis that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT05362578 · results posted 20 July 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT05362578) enrolled 41 people in total — 21 in the treatment group and 20 in a sham (inactive/comparison) group. The trial was looking at a condition called gastroparesis, which affects how the stomach empties food, and measured changes in stomach-related symptoms, quality of life, stomach function, and certain body signals (electrical activity in the stomach and heart) over about 12 weeks. By the end of the study, 15 people had completed the treatment group and 13 had completed the sham group. Notably, 13 of the sham group...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04254549 · results posted 22 June 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04254549) looked at whether an intervention treatment had any effect on bloating symptoms compared to a placebo (a dummy treatment with no active ingredient). A total of five people took part — four in the intervention treatment group and one in the placebo group. The trial measured changes in bloating and related symptoms using a combination of four questionnaires, covering quality of life, stomach symptoms, anxiety and depression, and digestive discomfort, with participants answering up to 45 questions in total. The rep...
-
NCT04869670 · results posted 22 May 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04869670) was designed to compare a procedure called G-POEM (a type of endoscopic procedure for a stomach-emptying condition called gastroparesis) against a sham procedure — meaning a fake or placebo procedure. The trial aimed to measure changes in stomach-related symptoms and quality of life in participants. However, the reported data shows that only two people were enrolled in the G-POEM group and no one was enrolled in the sham procedure group. Of the two people who started in the G-POEM group, only one completed the st...
-
NCT05004012 · results posted 29 April 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled participants across four groups: a Control group (6 people), a Gastroparesis group (8 people), a Functional Dyspepsia group (6 people), and a G-POEM group (0 people enrolled). In total, 20 people started the study. Of these, 17 completed it — all 6 in the Control group, 5 of 8 in the Gastroparesis group, and all 6 in the Functional Dyspepsia group. The trial was measuring physical characteristics of the stomach, including how often the stomach contracts, the size of the pylorus (the opening between the stomach and the...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04026997 · results posted 25 March 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04026997) enrolled 72 people in total across four groups. Thirty people received the investigational treatment at 10 mg twice daily (Cohort 1), 15 received it at 20 mg once daily (Cohort 2), 9 received it at 5 mg twice daily (Cohort 3), and 18 received a placebo (an inactive treatment used for comparison). Almost all participants finished the study — only one person in Cohort 1 did not complete it. The trial was measuring how the treatment affected the speed at which the stomach empties food, using a breath test, and also...
-
NCT06533527 · results posted 5 December 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT06533527) involved 60 people in total — 28 in one group and 32 in another. All 60 participants completed the study with no dropouts. The trial was looking at what happens when people take a GLP-1 medication (a type of medication commonly used for diabetes or weight management) before having an endoscopy — a procedure where a camera is passed into the stomach. Specifically, the study compared two groups: those who **continued taking their medication as normal** before the procedure, versus those who **held (paused) their do...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04303195 · results posted 28 August 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04303195) enrolled 161 people in total, split across four groups: 40 people received a 5 mg dose of NG101, 41 received a 10 mg dose, 40 received a 20 mg dose, and 40 received a placebo (a dummy treatment with no active ingredient). The trial was measuring changes in stomach-related symptoms — such as nausea, feeling full too quickly, feeling overly full after eating, abdominal pain, and vomiting — in people with a stomach condition called gastroparesis (where the stomach empties more slowly than normal). Participants rated...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03941288 · results posted 13 February 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 92 people across four groups: 25 received cannabidiol (CBD) and 23 received a placebo among participants with functional dyspepsia (a condition causing ongoing stomach discomfort without a clear physical cause), and 21 received CBD and 23 received a placebo among participants with gastroparesis (a condition where the stomach empties food more slowly than normal). Most participants finished the study — 22, 21, 20, and 22 people respectively completed it across the four groups. The trial measured how the stomach process...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT05270460 · results posted 21 July 2023
According to the results reported on ClinicalTrials.gov, this trial enrolled 25 people in total across three groups: 9 received a low dose of an investigational treatment called PCS12852 (0.1 mg), 8 received a higher dose (0.5 mg), and 8 received a placebo (a dummy treatment with no active ingredient). All 9 in the low-dose group and all 8 in the placebo group finished the trial, while 2 of the 8 in the higher-dose group did not complete it. The trial was measuring how the stomach emptied food (called "gastric emptying"), how much of the treatment was absorbed into the blood, and how participa...
-
NCT03587142 · results posted 15 June 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03587142) enrolled 96 people in total — 47 received buspirone and 49 received a placebo (a dummy pill with no active ingredient). By the end of the study, 39 people in each group had completed the trial. The trial was measuring changes in stomach-related symptoms — specifically feelings of fullness after eating, not being able to finish a normal meal, excessive fullness, loss of appetite, and an overall symptom score — over a 4-week period. Participants rated the severity of these symptoms on a scale from 0 (no symptoms) t...
-
NCT03712124 · results posted 5 January 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT03712124) enrolled 21 participants in total — 10 in the CNSA-001 group and 11 in the placebo group. The trial was studying a condition called gastroparesis (a disorder where the stomach empties more slowly than normal), and it was measuring things like how much liquid food participants could comfortably drink before feeling completely full, how quickly their stomachs emptied food, and how severe their stomach symptoms were over a 28-day period. The reported data shows that for the main measurement — the maximum amount of...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03420781 · results posted 22 December 2021
According to the results reported on ClinicalTrials.gov, this trial looked at a medication called relamorelin (given as a 10 microgram injection) compared to a placebo (an inactive injection) in people with diabetic gastroparesis — a condition where the stomach empties more slowly than normal due to diabetes. A total of 467 participants started the main 40-week treatment phase (236 on placebo, 231 on relamorelin), and a smaller group of 193 participants then went on to a further 6-week follow-up period. The trial tracked participants' daily symptom scores covering nausea, abdominal pain, bloat...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT03786380 · results posted 15 December 2021
According to the results reported on ClinicalTrials.gov, this trial involved 202 participants in total, spread across five different treatment groups. The groups varied in whether participants received the study drug relamorelin, a placebo (an inactive substance), or a combination of both across different stages of the trial. The trial was primarily measuring how many participants experienced notable medical events, unusual laboratory test results, changes in vital signs (such as blood pressure and heart rate), or unusual heart-tracing (ECG) results while on the study drug. The reported data...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT03383146 · results posted 23 November 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT03383146) enrolled 450 people in total — 148 in the placebo group and 302 in the relamorelin 10 μg group — though not all of them completed the study. The trial was looking at a condition called diabetic gastroparesis, where the stomach empties too slowly in people with diabetes. Participants rated four symptoms daily — nausea, stomach pain, feeling overly full after eating, and bloating — on a scale of 0 to 40, where higher numbers mean worse symptoms. The trial measured how much those scores changed over 12 weeks and 52...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT04684992 · results posted 24 August 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT04684992) enrolled 36 participants, of whom 34 completed the study and 2 did not finish. The trial was looking at whether people could carry out a specific breath test — called the Gastric Emptying Breath Test (GEBT), which measures how quickly the stomach empties — entirely from home, guided by a health professional via telehealth (a video or phone call). The test involved drinking a special liquid containing a substance called 13C-Spirulina, collecting breath samples at set times, filling in a request form, and then post...
-
NCT03285308 · results posted 29 July 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT03285308) enrolled 336 people with diabetic gastroparesis — a condition where the stomach empties more slowly than normal in people with diabetes. Participants were randomly assigned to receive either a placebo (an inactive treatment) or a drug called relamorelin (10 micrograms), with 167 people starting in the placebo group and 169 in the relamorelin group. The trial ran for 12 weeks and measured changes in four stomach-related symptoms — nausea, abdominal pain, bloating, and feeling full after eating — as well as vomitin...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01989221 · results posted 26 May 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT01989221) enrolled 14 participants, and all 14 completed the study. The trial was a crossover design, meaning participants first received a placebo (an inactive treatment) and then received Sancuso — a skin patch containing a medicine called granisetron, sometimes referred to as GTS. The trial was measuring the severity of stomach-related symptoms in people with a condition called gastroparesis (where the stomach is slow to empty), using a daily symptom diary called the GCSI-DD. This diary asked participants to rate sympto...
-
NCT03342157 · results posted 23 October 2020
According to the results reported on ClinicalTrials.gov, this trial (NCT03342157) enrolled a very small number of participants — just two people in total, one assigned to a high-dose group and one to a low-dose group. Both participants completed the study without dropping out. The trial was measuring stomach-related symptoms using a tool called the Modified Gastroparesis Cardinal Symptom Index-Daily Diary (mGCSI-DD), which asks people to rate symptoms like nausea or fullness on a scale from 0 (no symptoms) to 5 (very severe). It also looked at how often participants used extra "breakthrough" m...
-
NCT02025751 · results posted 7 July 2020
According to the results reported on ClinicalTrials.gov, this trial involved 53 people in total — 26 received a metoclopramide nasal spray and 27 received a placebo (dummy) nasal spray. The trial was looking at symptoms of a stomach condition called gastroparesis, where the stomach is slow to empty. Participants rated their symptoms daily using a questionnaire called the Gastroparesis Symptom Assessment (GSA), which runs on a scale from 0 (no symptoms) to 4 (very severe symptoms). The main thing being measured was how much those symptom scores changed from the start of the trial to the end of...
-
NCT02025725 · results posted 11 February 2020
According to the results reported on ClinicalTrials.gov, this trial looked at a nasal spray version of a medicine called metoclopramide (at a dose of 10 mg) compared to a dummy (placebo) nasal spray, in people with a stomach condition called gastroparesis — where the stomach empties more slowly than normal. A total of 102 people were assigned to the metoclopramide nasal spray group and 103 to the placebo group. By the end of the study, 91 people in the active spray group and 99 in the placebo group had completed the trial. The main thing being measured was a symptom score called the Gastropar...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03268941 · results posted 23 July 2019
According to the results reported on ClinicalTrials.gov, this trial (NCT03268941) studied an investigational medicine called TAK-906 Maleate, given at three different doses (5 mg, 25 mg, and 100 mg), compared to a placebo (inactive treatment) and, in a separate part of the trial, compared to an existing medicine called metoclopramide (10 mg). The trial was split into two parts. In Part 1, a total of 51 people took part across the placebo and three TAK-906 dose groups. In Part 2, a smaller group of participants (around 6 to 15 people per group) received TAK-906 25 mg either with food or fasted,...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00595621 · results posted 31 May 2019
According to the results reported on ClinicalTrials.gov, this trial looked at a device called MGP-1, which was tested in people with a stomach condition called gastroparesis (where the stomach empties food more slowly than normal). The trial started with 22 participants in an open run-in phase, where everyone used the device switched on. Of those, 19 completed that phase, and 19 were then randomly assigned to one of two groups — 10 with the device turned "ON" and 9 with it turned "OFF" — to compare what happened under each condition over up to three months. The reported data shows that the ma...
-
NCT01030341 · results posted 4 September 2018
According to the results reported on ClinicalTrials.gov, this trial enrolled 45 people in total, all of whom had diabetes with a condition called gastroparesis (a stomach-emptying problem). Forty-two participants completed the study, and three did not finish. The trial was measuring whether using a continuous glucose monitor (a small device that tracks blood sugar levels throughout the day) combined with an insulin pump changed the rate of low blood sugar episodes, stomach symptoms, and quality of life over 24 weeks, compared to a screening period beforehand. The reported data shows that low...
-
NCT02130622 · results posted 17 May 2018
According to the results reported on ClinicalTrials.gov, this trial was comparing promethazine (a medication sometimes used for nausea) against a sugar pill (placebo) in people with a stomach condition called gastroparesis — where the stomach empties more slowly than normal. The trial set out to measure changes in self-reported symptoms using a standard symptom scoring tool, as well as tracking any unwanted effects, use of a backup medication, and the impact on participants' ability to work and carry out daily activities. The reported data shows that only three people took part in the trial i...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01934192 · results posted 9 November 2017
According to the results reported on ClinicalTrials.gov, this trial enrolled 92 people in total across four groups. Most participants (40 and 44 people respectively) were already tolerating tube feeding at the start and were given either a placebo followed by camicinal, or camicinal followed by metoclopramide (another medicine). A smaller group of 8 people who were not tolerating tube feeding were given either camicinal or metoclopramide. The trial was measuring how much of a person's prescribed tube-feeding nutrition they actually received, and was comparing a drug called camicinal (50 mg) ag...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT02210000 · results posted 1 November 2017
According to the results reported on ClinicalTrials.gov, this trial involved 114 people in total — 57 who received a medicine called camicinal (25 mg) and 57 who received a placebo (a dummy treatment with no active ingredient). The trial was studying people with a stomach condition called gastroparesis, where the stomach empties more slowly than normal. The main thing the trial was measuring was how many people reported meaningful improvement in feelings of fullness and early satiety (feeling full very quickly after starting to eat) after 12 weeks, using a patient-reported symptom diary called...
-
NCT01262898 · results posted 13 October 2017
According to the results reported on ClinicalTrials.gov, this trial enrolled 79 people across four groups: 21 received a placebo (a dummy treatment with no active ingredient), 18 received a 10 mg dose of GSK962040, 18 received a 50 mg dose, and 22 received a 125 mg dose. The trial was measuring how quickly the stomach emptied its contents in people who took the study drug compared to those who took the placebo. Stomach emptying was tracked using a breath test that detected a harmless, non-radioactive marker added to a test meal. The main outcome being measured was the time it took for the stom...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT00492622 · results posted 28 July 2017
According to the results reported on ClinicalTrials.gov, this trial enrolled 12 participants, and all 12 completed the study with none dropping out. The trial was comparing two different formulations of omeprazole (a medication commonly used for stomach acid) — an immediate-release version and a delayed-release version. The study was measuring how the drug moved through participants' bodies, specifically how quickly it reached its highest level in the blood, how high that peak level was, and the total amount of the drug that was absorbed over time. The reported data shows the following number...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01892267 · results posted 17 May 2017
According to the results reported on ClinicalTrials.gov, this trial enrolled 19 people who needed a type of feeding tube called a PEG-J tube — a tube inserted through the stomach wall to deliver nutrition directly into the small intestine. Participants were split into two groups: 9 people received a "self-propelled" version of this tube, and 10 received a standard version. All 19 participants completed the study. The trial was primarily looking at how often the tube moved out of position (called "migration") within 4 weeks of being placed, and also tracked a number of secondary measures such a...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT01602549 · results posted 6 February 2017
According to the results reported on ClinicalTrials.gov, this trial (NCT01602549) enrolled 57 people in total — 19 received a placebo (a dummy treatment with no active ingredient) and 38 received the investigational drug GSK962040. Nearly all participants finished the study: 18 in the placebo group and 37 in the GSK962040 group completed it, with just one person leaving each group early. The trial was measuring how a drug called levodopa (L-DOPA, a common Parkinson's disease medication) was absorbed into the bloodstream when GSK962040 was also given — specifically looking at the amount of levo...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
See all 36 reported results for Gastroparesis
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, a moderate amount of public research funding has been directed toward gastroparesis, which suggests the condition has attracted meaningful scientific attention at a government level. However, the direction of that funding has been falling year on year, which may mean that research interest or government prioritisation is shifting away from this area over time. For pa...
See the full Gastroparesis page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.